BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$66.60 USD
+0.71 (1.08%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $66.63 +0.03 (0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.60 USD
+0.71 (1.08%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $66.63 +0.03 (0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
Zacks News
Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug
by Zacks Equity Research
Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.
Biotech Stock Roundup: REGN's Cocktail Approval, Updates From BMY, BMRN & VRTX
by Zacks Equity Research
The biotech sector was in focus last week on updates form Regeneron (REGN) and Bristol Myers (BMY).
Vertex (VRTX) Initiates Phase II Study on Pain Candidate
by Zacks Equity Research
Vertex (VRTX) starts phase II study for VX-548 to treat acute pain after bunionectomy surgery & expects to start another phase II study to treat acute pain after abdominoplasty surgery in a few weeks.
Synlogic's (SYBX) Begins Phase I Study for PKU Treatment
by Zacks Equity Research
Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.
BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy
by Zacks Equity Research
The EMA validates BioMarin's (BMRN) marketing application for valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
QIAGEN (QGEN), Sysmex Ink Cancer Companion Diagnostics Deal
by Zacks Equity Research
QIAGEN (QGEN) and Sysmex collaborate to develop and commercialize cancer companion diagnostics.
BioMarin (BMRN) Re-Files MAA for Hemophilia Gene Therapy in EU
by Zacks Equity Research
Biomarin Pharmaceutical's (BMRN) new MAA in EU includes 52 weeks' data from the phase III GENEr8-1 study, along with four and three-year follow-up data from the ongoing phase I/II dose escalation study.
BioMarin's (BMRN) Vosoritide Gets CHMP Nod to Treat Dwarfism
by Zacks Equity Research
Biomarin Pharmaceutical (BMRN) receives positive recommendation from Europe's CHMP for vosoritide to treat achondroplasia in children.
BioMarin (BMRN) Hemophilia Gene Therapy Gets EMA's Speedy Review
by Zacks Equity Research
The EMA grants accelerated assessment to BioMarin's (BMRN) request for review of valoctocogene roxaparvovec for treating severe hemophilia A.
BioMarin (BMRN) Q1 Earnings Beat, FDA Delays Vosoritide Decision
by Zacks Equity Research
BioMarin (BMRN) beats estimates for both earnings and revenues in the first quarter of 2021.
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 75.00% and 9.11%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin (BMRN) Down 7.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag
by Zacks Equity Research
FDA grants RMAT designation to BioMarin's (BMRN) gene therapy for severe hemophilia A, valoctocogene roxaparvovec, after rejecting it last year.
BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull
by Zacks Equity Research
BioMarin (BMRN) beats estimates for both earnings and sales in the fourth quarter. Sales guidance for 2021 falls short of investor expectation.
Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline
by Zacks Equity Research
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALXN vs. BMRN: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALXN vs. BMRN: Which Stock Is the Better Value Option?
ALXN vs. BMRN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. BMRN: Which Stock Is the Better Value Option?
Stock Market News for Jan 12, 2021
by Zacks Equity Research
Benchmarks declined from record highs on Monday as investors weighed impact of rise in coronavirus cases and ongoing political turmoil on economic growth.
BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy
by Zacks Equity Research
BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemophilia A.
ALXN or BMRN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. BMRN: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals
4 Biotechs That Could Be Potential Acquisition Targets in 2021
by Zacks Equity Research
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.
Why Is BioMarin (BMRN) Up 6.1% Since Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate
by Zacks Equity Research
Pfizer (PFE) doses the first participant in the late-stage BASIS study, currently investigating marstacimab to address severe hemophilia A or B with or without inhibitors.